No, baldness will not be cured by 2025. The most promising treatments in development are still in early or mid-stage clinical trials, and none will reach the market this year. But the pipeline is more active than it has been in decades, with several new approaches showing real results in humans for the first time. Here’s where things actually stand.
Why Progress Has Been So Slow
Only two drugs have ever been approved by the FDA for common pattern hair loss: minoxidil (approved in 1988) and finasteride (approved in 1997). That’s a nearly 30-year gap with no new options reaching the market. The core problem is biological complexity. Hair follicles cycle through growth, rest, and shedding phases controlled by dozens of signaling pathways, and the hormonal sensitivity that drives pattern baldness involves deep changes in follicle structure over time. Treatments that look promising in mice frequently fail in humans because human hair follicles behave differently and cycle on much longer timescales.
The Closest New Drug: Clascoterone
The treatment nearest to approval is clascoterone, a topical solution that blocks the hormone receptors on hair follicles responsible for miniaturization. It works at the scalp rather than systemically, which could avoid the sexual side effects that make some men reluctant to take finasteride. Phase III results have been described as a breakthrough by the manufacturer, Cosmo Pharmaceuticals.
However, the company won’t complete its required 12-month safety follow-up until spring 2026, with regulatory submissions in the U.S. and Europe planned after that. A realistic approval date is late 2027 at the earliest. If approved, clascoterone would be the first topical androgen receptor inhibitor for pattern hair loss, a genuinely new class of treatment. But it’s a maintenance therapy, not a cure.
A New Type of Topical Treatment
One of the more interesting drugs in the pipeline is GT20029, developed by Kintor Pharmaceutical. Rather than simply blocking hormone receptors, it degrades the receptors themselves. In a Phase II trial completed in 2024, participants using the topical treatment saw statistically significant hair regrowth at 12 weeks compared to placebo. The group applying a 1% concentration twice weekly gained roughly 12 hairs per square centimeter versus about 5 in the placebo group, and hair thickness also improved meaningfully.
Side effects were mostly mild and occurred at similar rates across all groups, including placebo. A Phase III trial is now being designed, but no completion date has been announced. Even with favorable results, this drug is likely several years from reaching pharmacies.
Alopecia Areata Now Has Real Treatments
There’s one area where genuine breakthroughs have already arrived, though it involves a different type of hair loss. Alopecia areata, an autoimmune condition where the immune system attacks hair follicles, now has three FDA-approved treatments. All belong to a class called JAK inhibitors: baricitinib was approved in June 2022, ritlecitinib in June 2023, and deuruxolitinib in July 2024. Additional options like upadacitinib are in clinical trials.
These are significant for people with alopecia areata, which can cause patchy or total hair loss across the scalp and body. But they don’t work for the far more common androgenetic alopecia (pattern baldness), which has a completely different mechanism. If your hair loss follows the typical receding hairline or thinning crown pattern, JAK inhibitors won’t help.
Hair Cloning and Stem Cell Approaches
The most ambitious research aims to grow entirely new hair follicles from a patient’s own cells. Stemson Therapeutics, founded in 2018, is developing a method that uses reprogrammed stem cells to create follicular units through a proprietary bioprinting process. These engineered structures combine hair follicle cells and biomaterials into a three-dimensional design that mimics natural follicle architecture.
The company recently announced that its bioengineered follicular units successfully generated human hair growth in humanized mice, a significant technical milestone. Growing human hair from lab-built structures in living skin is a prerequisite for human trials, and Stemson has described this as the final development stage before testing in patients. But “pre-clinical stage” means human trials haven’t started yet, and cell therapies typically face years of regulatory review even after successful trials. A commercially available product is likely a decade or more away.
Signaling Molecules That Wake Up Follicles
Researchers at UC Irvine identified a naturally occurring protein called SCUBE3 that dermal papilla cells use to signal neighboring stem cells to begin dividing, which kicks off new hair growth. When the team injected SCUBE3 into mouse skin containing transplanted human scalp follicles, it triggered growth in both the dormant human follicles and surrounding mouse follicles.
This is compelling because it targets the natural wake-up signal that follicles already use. The university has filed a patent, and further research is being conducted in partnership with a biotech company. But this remains in the proof-of-concept stage. No human clinical trials have been announced, and translating a microinjection study into a practical treatment people can use at home or in a clinic is a long process.
Scarless Healing and Follicle Regeneration
A separate line of research at Stanford has found that a drug called verteporfin, already FDA-approved for an eye condition, can reduce scarring after skin wounds and regenerate hair follicles and sweat glands that are normally lost during scar formation. This matters for hair restoration because the donor area in hair transplant surgery typically scars, limiting how many grafts can be harvested. If verteporfin could prevent that scarring and allow follicle regeneration, it could dramatically improve transplant outcomes.
This is still at the proof-of-concept stage. The fact that verteporfin already has FDA safety data as an injectable could shorten the path to clinical trials, but no human hair loss trials have been announced.
What This All Means Practically
If you’re losing your hair now, the options available today are the same ones that have existed for years: minoxidil (topical), finasteride (oral), and hair transplant surgery. These work for many people, particularly when started early, but none reverse advanced baldness completely, and both medications require ongoing use.
The pipeline is genuinely more promising than at any point in the past three decades. Multiple new mechanisms are being tested in humans, stem cell technology has reached the point of generating real hair from engineered structures, and new drug classes are in late-stage trials. But the timelines are measured in years, not months. The most optimistic scenario puts a new FDA-approved drug for pattern baldness (clascoterone) on the market around 2027. Cell-based therapies that could restore lost follicles are further out still.
Baldness won’t be cured by 2025. The more realistic question is whether the next five to ten years will finally deliver treatments that go meaningfully beyond what minoxidil and finasteride can do. Based on the current science, that looks increasingly likely.